AKT1 and metabolic dysfunction-associated steatotic liver disease: The activator of the lipid synthesis signaling pathway on which PI3K/Akt depends is mTOR, and the abnormalities of the above signaling pathways affect the utilization of fatty acid synthesis substrates in hepatocytes, leading to the occurrence of metabolic inflammation, ultimately forming insulin resistance and promoting the development of nonalcoholic fatty liver disease (26).